Peter Edward Fecci
Associate Professor of Neurosurgery
As the Director of both the Brain Tumor Immunotherapy Program and the Center for Brain and Spine Metastasis at Duke University, I focus our programmatic interests on the design, optimization, and monitoring of immune-based treatment platforms for patients with intracranial tumors, whether primary or metastatic. Within this broad scope, however, my own group looks more specifically at limitations to immunotherapeutic success, with a particular focus on understanding and reversing T cell dysfunction in patients with glioblastoma (GBM) and brain metastases. We employ a systematic approach to categorizing T cell dysfunction (Woroniecka et al, Clin Cancer Res 2018 Aug 15;24(16):3792-3802), and whereas our earlier work addressed concerns for regulatory T cell-induced tolerance, we now heavily study T cell ignorance and exhaustion, as well. Regarding the former, we recently published the novel phenomenon of S1P1-mediated bone marrow T cell sequestration in patients with intracranial tumors (Chongsathidkiet et al, Nat Medicine 2018 Sep;24(9):1459-1468). Regarding the latter, we have likewise recently identified and characterized exhaustion as a significant limitation to T-cell function within GBM (Woroniecka et al, Clin Cancer Res 2018 Sep 1;24(17):4175-4186). I very much look to collaboratively integrate our approaches with others investigating innovative treatment options. I continue my focus on combining strategies for reversing T cell deficits with current and novel immune-based platforms as a means of deriving and improving rational and precise anti-tumor therapies. It is my sincerest desire to forge a career focused on co-operative, multi-disciplinary, organized brain tumor therapy. Ultimately, my goal is to help coordinate the efforts of a streamlined and effective center for brain tumor research and clinical care. I hope to play some role in ushering in a period where the science and treatment arms of brain tumor therapy suffer no disjoint, but instead represent the convergent efforts of researchers, neuro-oncologists, medical oncologists, radiation oncologists, biomedical engineers, and neurosurgeons alike. I hope to see such synergy become standard of care.
Appointments and Affiliations
- Associate Professor of Neurosurgery
- Assistant Research Professor in Immunology
- Associate Professor in Pathology
- Member of the Duke Cancer Institute
- Office Location: 201 Sands Bldg., Box 3050, Durham, NC 27710
- Office Phone: (919) 681-2610
- Email Address: email@example.com
- Massachusetts General Hospital, 2014
- Dana Farber Cancer Institute, 2012
- Massachusetts General Hospital, 2013
- Massachusetts General Hospital, 2008
- Ph.D. Duke University, 2007
- M.D. Duke University School of Medicine, 2007
Brain Tumor Immunotherapy
Cancer-Induced Immune Dysfunction
Awards, Honors, and Distinctions
- Paper of the Year. American Association of Physicists in Medicine. 2017
- Visting Scholar. National Institutes of Health. 2017
- Duke Health Scholars Award. Duke University School of Medicine. 2016
- Prince Mahidol Youth Mentor Award. Prince Mahidol Award Foundation. 2016
- Alpha Omega Alpha. Alpha Omega Alpha Medical Honor Society. 2015
- Resident Advocate Award. Duke University Department of Neurosurgery. 2015
- Sontag Distinguished Scientist Award. Sontag Foundation. 2015
- Matson Award for Best Basic Science Research. New England Neurosurgical Society. 2013
- Preuss Award for Neuro-Oncologic Research. Congress of Neurological Surgeons. 2013
- NIH Loan Repayment Program Award. National Institutes of Health. 2011
- Resident Teaching Award. Tufts University School of Medicine. 2008
- Neurosurgery Award. Duke University Department of Neurosurgery. 2007
- Keynote Speaker. Society for Neuro-Oncology. 2006
- Eugene A. Stead Scholar. Duke University School of Medicine. 2001
- Medical Scientist Training Program Fellowship. National Institutes of Health. 2001
- Cornell-Diamante Scholarship. Cornell University. 1999
- Merrill Presidential Scholar. Cornell University. 1999
- Nanaline H. Duke Scholar. Duke University School of Medicine. 1999
- MOLMED 301B: Research in MOLMED - Oncological Sciences
- NSS 301B: Research in NSS
- PATHOL 793: Research Independent Study
In the News
- A Duke Team Just Found Missing Immune Cells That Could Fight Lethal Brain Tumors (Aug 13, 2018 | Duke Health News)
- Duke neurosurgeon: Many factors in McCain's favor as he undergoes cancer treatment (Jul 20, 2017)
- Sampson, JH; Gunn, MD; Fecci, PE; Ashley, DM, Brain immunology and immunotherapy in brain tumours., Nat Rev Cancer, vol 20 no. 1 (2020), pp. 12-25 [10.1038/s41568-019-0224-7] [abs].
- Woroniecka, KI; Rhodin, KE; Dechant, CA; Waibl Polania, J; Chongsathidkiet, P; Wilkinson, D; Cui, X; Sanchez-Perez, L; Fecci, PE, 4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers., Clinical Cancer Research : an Official Journal of the American Association for Cancer Research (2019) [10.1158/1078-0432.CCR-19-1068] [abs].
- Kirkpatrick, JP; Fecci, PE, Offer Hypofractionated SRS… If Her Performance Status Is Good., Int J Radiat Oncol Biol Phys, vol 105 no. 5 (2019), pp. 940-941 [10.1016/j.ijrobp.2018.07.001] [abs].
- Mohammadi, AM; Sharma, M; Beaumont, TL; Juarez, KO; Kemeny, H; Dechant, C; Seas, A; Sarmey, N; Lee, BS; Jia, X; Fecci, PE; Baehring, J; Moliterno, J; Chiang, VL; Ahluwalia, MS; Kim, AH; Barnett, GH; Leuthardt, EC, Upfront Magnetic Resonance Imaging-Guided Stereotactic Laser-Ablation in Newly Diagnosed Glioblastoma: A Multicenter Review of Survival Outcomes Compared to a Matched Cohort of Biopsy-Only Patients., Neurosurgery, vol 85 no. 6 (2019), pp. 762-772 [10.1093/neuros/nyy449] [abs].
- Kemeny, HR; Elsamadicy, AA; Farber, SH; Champion, CD; Lorrey, SJ; Chongsathidkiet, P; Woroniecka, KI; Cui, X; Shen, SH; Rhodin, KE; Tsvankin, V; Everitt, J; Sanchez-Perez, L; Healy, P; McLendon, RE; Codd, PJ; Dunn, IF; Fecci, PE, Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease., Clinical Cancer Research : an Official Journal of the American Association for Cancer Research (2019) [10.1158/1078-0432.CCR-18-3486] [abs].